APR 19, 2017 8:02 PM PDT

Resilient T Cells Provide Cancer Treatment and Immunity

WRITTEN BY: Kara Marker

A key part of the process to create immunotherapies for the treatment of cancer involves rapid expansion protocols (REPs) and immune cells extracted from hosts. The idea is to put the immune cells back once they have been altered to be bigger and better at killing cancer, but previous targets, namely CD8+ T cells, lose their power after going through REPs. However, scientists have now identified a better target cell that could completely change immunotherapy approaches.

FierceBiotech

CD8+ T cells might not be cut out for long-term REPs, a necessary step in adoptive cancer immunotherapy (ACT). Th17 cells, though, appear to be uniquely eligible for the task; as compared to CD8+ T cells that show reduced efficacy after going through REPs, Th17 cells are more resilient and durable throughout the expansion process.

As an immunotherapy approach, ACT revolves around “The Three Es:” extracting, expanding, and enhancing host T cells for eventual return to the body to fight cancer. REPs are necessary but tough on T cells, and it can take up months to adequately prepare cells. After several weeks of preparation, CD8+ T cells often lose their power, but Th17 cells have been shown to be “resistant to expansion-induced degradation,” making them an obvious replacement for the seemingly “delicate” CD8+ cells.

"Th17 cells have a natural propensity to logarithmically expand without restimulation,” explained research leader Chrystal Paulos, PhD. “And, if we did restimulate them, this approach didn't dramatically impair the antitumor response as with CD8+ T cells."

What makes Th17 cells special? Stem cell-like properties. Paulos’s study showed that Th17 cells produced five thousand times the original number of cells when expanded for three weeks outside of the body thanks to their “natural propensity.”

Credit: Dr. Chrystal Paulos and Jacob Bower

In addition to retaining stem memory, resisting degradation, and effectively targeting melanoma in a mice model, after extraction and two weeks of expansion Th17 cells also remained in the tumor-bearing host after being returned to the body, indicating a protective effect for any possible recurrences of the cancer.

“When we rechallenged the same animals with another lethal tumor dose, these mice were protected but the control mice died quickly,” Paulos said. “Then we came back again 100 days later and gave these mice lung tumors and they were all still protected many months later."

Even more promising, the “remarkably potent antitumor response” seems to be extendable to the treatment of other cancer types, with an anti-cancer immunity effect “superior” to that obtained by classic applications of immunotherapy.

Sources: Medical University of South Carolina, JCI Insight

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 15, 2019
Immunology
SEP 15, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
SEP 24, 2019
Immunology
SEP 24, 2019
Flu Shot Less Effective Due to Overuse of Antibioitics
New research out of the Stanford University School of Medicine shows that the consequence of overuse of antibiotics lowers the effectiveness of the seasona...
OCT 16, 2019
Immunology
OCT 16, 2019
Coffee Bean Extracts for Fat-induced Inflammation
One man’s coffee trash is another man’s solution for addressing chronic inflammation. A new Food and Chemical Toxicology study illustrates the ...
OCT 25, 2019
Drug Discovery & Development
OCT 25, 2019
Novel Therapeutic For Eradicating The Flu Virus
Public Health officials have long warned about pandemic pathogens flying fast around the world. One virus already spreads across the globe annually leading...
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
FEB 10, 2020
Immunology
FEB 10, 2020
How Cancer Evades the Immune System Time and Time Again
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying...
Loading Comments...